This lack of cardiac effect with ST2/IL-33 pathway inhibition observed in the Phase II trials is particularly encouraging given that the patient populations enrolled in these trials (for example, patients with COPD who experience frequent exacerbations and patients with severe COVID-19) are considered to be at risk of cardiac events [42, 43]. The gene discussed is IL33; the disease is COVID-19.